公开(公告)号：US20180319888A1

公开(公告)日：2018-11-08

申请号：US15977725

申请日：2018-05-11

Applicant: Genmab A/S

Inventor： Aran Frank Labrijn ,  Stefan Loverix ,  Paul Parren ,  Jan Van De Winkel ,  Janine Schuurman ,  Ignace Lasters

IPC: C07K16/28 ,  C07K16/00 ,  A61K47/68 ,  A61K51/10 ,  A61K39/395

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K47/6849 ,  A61K51/103 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/76

Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.

公开(公告)号：US20150376282A1

公开(公告)日：2015-12-31

申请号：US14739768

申请日：2015-06-15

Applicant: Genmab A/S

Inventor： Aran Frank Labrijn ,  Stefan Loverix ,  Paul Parren ,  Jan Van De Winkel ,  Janine Schuurman ,  Ignace Laster

IPC: C07K16/28 ,  A61K47/48 ,  A61K51/10 ,  A61K39/395

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K47/6849 ,  A61K51/103 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/76

Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.

Abstract translation: 本发明涉及抗体的恒定区，特别是IgG4的CH3区的位置，其影响了CH3-CH3相互作用的强度。 公开了稳定或不稳定这种相互作用的突变。

公开(公告)号：US20150175707A1

公开(公告)日：2015-06-25

申请号：US14413178

申请日：2013-07-05

Applicant: GENMAB B.V.

Inventor： Rob N. De Jong ,  Frank Beurskens ,  Paul Parren ,  Aran Frank Labrijn ,  Janine Schuurman ,  Arjen Vlug ,  Sandra Verploegen

IPC: C07K16/40 ,  C07K16/12 ,  C07K16/28

Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

Abstract translation: 本发明涉及包含不同于存在于人IgG1中的三个不同位置的氨基酸的二聚体蛋白质。 所述二聚体蛋白中的六个能够在溶液中形成六聚体结构。

公开(公告)号：US20140093454A1

公开(公告)日：2014-04-03

申请号：US13964956

申请日：2013-08-12

Applicant: Genmab A/S

Inventor： Jessica Teeling ,  Sigrid Ruuls ,  Martin Glennie ,  Jan G.J. van de Winkel ,  Paul Parren ,  Jørgen Petersen ,  Ole Baadsgaard ,  Haichun Huang

IPC: C07K16/28 ,  A61K45/06 ,  G01N33/68 ,  A61K39/395

CPC classification number: C07K16/2887 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/4258 ,  C07K2317/21 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/686

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了结合并抑制人CD20的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的转染瘤或非人转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US12247065B2

公开(公告)日：2025-03-11

申请号：US17253286

申请日：2019-06-24

Applicant: GENMAB A/S

Inventor： Richard Hibbert ,  Rob De Jong ,  Aran Frank Labrijn ,  Arnout Gerritsen ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/00 ,  C07K1/18 ,  C07K1/22

Abstract: The present invention relates to a method for controlling the composition of a mixture of two or more different antibodies, such as tow or more different monoclonal antibodies, using chromatography. The mixture is for use as a drug product and the method includes a controlled downstream process for the production of a predetermined ratio of the two or more different antibodies.

公开(公告)号：US20240084036A1

公开(公告)日：2024-03-14

申请号：US17972867

申请日：2022-10-25

Applicant: Genmab A/S

Inventor： Joost J. NEIJSSEN ,  Bart De Goeij ,  Edward Norbert Van Den Brink ,  Aran Frank Labrijn ,  Rene Hoet ,  Janine Schuurman ,  Paul Parren ,  Jan Van De Winkel

IPC: C07K16/30 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C07K16/40 ,  G01N33/574

CPC classification number: C07K16/3076 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2863 ,  C07K16/40 ,  G01N33/5748 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/71 ,  G01N2333/912

Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US11613575B2

公开(公告)日：2023-03-28

申请号：US16544376

申请日：2019-08-19

Applicant: GENMAB A/S

Inventor： Edward Norbert Van Den Brink ,  Joost J. Neijssen ,  Aran Frank Labrijn ,  Joyce Meesters ,  Janine Schuurman ,  Isil Altintas ,  Paul Parren ,  Rik Rademaker

IPC: A61P35/00 ,  C07K16/28 ,  C07K16/32 ,  C07K16/10 ,  C07K16/42 ,  G01N33/68 ,  A61K39/00

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US11130819B2

公开(公告)日：2021-09-28

申请号：US17228023

申请日：2021-04-12

Applicant: GENMAB A/S

Inventor： David Satijn ,  Esther C. W. Breij ,  Bart E. C. G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K39/00

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US11091553B2

公开(公告)日：2021-08-17

申请号：US15832337

申请日：2017-12-05

Applicant: GENMAB A/S

Inventor： Bart De Goeij ,  Simone De Haij ,  Thilo Riedl ,  Rene Hoet ,  Ole Baadsgaard ,  Jan Van De Winkel ,  David Satijn ,  Paul Parren ,  Aran Frank Labrijn ,  Joyce Meesters ,  Janine Schuurman ,  Edward N. Van Den Brink

IPC: C07K16/28 ,  C07K16/32 ,  A61K39/00

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US11084882B2

公开(公告)日：2021-08-10

申请号：US16855703

申请日：2020-04-22

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Friederike Gieseke ,  Ugur Sahin

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.